Top Partnering Opportunities in CV/Metabolics: A Shifting Marketplace
Executive SummaryHigher barriers to entry have made deals in the cardiovascular and metabolics spaces increasingly difficult, but novel therapeutic approaches coupled with unmet metabolic need – especially in type 2 diabetes – are keeping both of these fields top of mind.
You may also be interested in...
India’s Indoco Remedies is looking for healthy revenue growth in the coming fiscal year after beating market estimates with a 70.4% year-on-year jump in after-tax profit in its financial third quarter, propelled by strong revenues from domestic and international markets.
The Committee on Energy and Commerce of the US House of Representatives has requested a set of documents from the FDA in order to assess whether the agency is doing enough to address the challenge of approving complex generics within its existing authorities, or whether additional authority is needed.
As industry bellwether J&J kicked-off 2019 fourth-quarter and full-year earnings season for life sciences companies, its financial results left investors feeling the cold. But with coronavirus envy sweeping a raft of smaller biotech companies, J&J may have the last laugh.